Combination therapy may improve immune response against advanced prostate cancer
A Northwestern Medicine study suggests that combining olaparib with immunotherapy can improve outcomes for patients with metastatic castration-resistant prostate cancer. This approach aims to sensitize 'immune-cold' tumors to treatment in patients who have failed initial therapies.
Why it matters
This research offers a potential new treatment pathway for an aggressive form of cancer with limited options.
by Melissa Rohman, Northwestern University
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Graphical abstract. Credit: Journal of Clinical Investigation (2026). DOI: 10.1172/jci203785 Combining the targeted therapy olaparib with an additional immunotherapy may improve immune response in a subgroup of patients with metastatic castration-resistant prostate cancer who responded poorly to initial treatment, according to a Northwestern Medicine study published in The Journal of Clinical Investigation.
"We identified a new combination therapy strategy to overcome immune-cold tumors and sensitize them to immunotherapy," said Bin Zhang, MD, Ph.D., the Johanna Dobe Professor of Cancer Immunology, who was senior author of the study.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in